Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July
Portfolio Pulse from Lisa Levin
The article lists the top 5 oversold health care stocks with an RSI near or below 30, which could lead to significant gains in July. The companies mentioned are Cibus, Inc. (CBUS), Panbela Therapeutics, Inc. (PBLA), Vor Biopharma Inc. (VOR), Innovative Eyewear, Inc. (LUCY), and Bellerophon Therapeutics, Inc. (BLPH). All these stocks have seen a recent dip in their prices.
July 05, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cibus recently closed its merger with Calyxt, Inc. and has over 1,000 patents issued or pending. Its stock fell 4.9% to close at $9.99 on Monday.
The recent merger with Calyxt and the large number of patents could potentially drive the stock price up in the short term despite the recent dip.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Innovative Eyewear recently announced a new retail partnership with PRIVATO duty-free. Its stock fell 3.7% to close at $0.8611 on Monday.
The new retail partnership could potentially increase the company's value and drive the stock price up in the short term despite the recent dip.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Panbela Therapeutics has been granted a European patent for its lead investigational product. Its stock fell 4.8% to close at $2.19 on Monday.
The new patent could potentially increase the company's value and drive the stock price up in the short term despite the recent dip.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Vor Biopharma recently presented updated data from its VBP101 Phase 1/2a study. Its stock dipped 4.2% to close at $2.96 on Monday.
The updated data from the VBP101 study could potentially increase the company's value and drive the stock price up in the short term despite the recent dip.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Bellerophon Therapeutics approved a reduction-in-force of substantially all of its employees. Its stock fell 2.6% to close at $0.6723 on Monday.
The reduction-in-force could potentially decrease the company's value and drive the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100